Vanguard Group
RLMD icon

Vanguard Group’s Relmada Therapeutics RLMD Stock Holding History

Vanguard Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.81M Buy
1,203,307
+784,727
+187% +$2.63M ﹤0.01% 3194
2025
Q3 		$841K Buy
418,580
+54,503
+15% +$52.3K ﹤0.01% 3834
2025
Q2 		$218K Sell
364,077
-843,998
-70% -$433K ﹤0.01% 4076
2025
Q1 		$326K Sell
1,208,075
-48,630
-4% -$16.1K ﹤0.01% 3980
2024
Q4 		$653K Hold
1,256,705
– – ﹤0.01% 3873
2024
Q3 		$4.07M Hold
1,256,705
– – ﹤0.01% 3345
2024
Q2 		$3.77M Hold
1,256,705
– – ﹤0.01% 3371
2024
Q1 		$5.84M Sell
1,256,705
-54,100
-4% -$261K ﹤0.01% 3240
2023
Q4 		$5.43M Buy
1,310,805
+770
+0.1% +$2.28K ﹤0.01% 3255
2023
Q3 		$3.93M Hold
1,310,035
– – ﹤0.01% 3347
2023
Q2 		$3.22M Sell
1,310,035
-194,944
-13% -$539K ﹤0.01% 3492
2023
Q1 		$3.4M Sell
1,504,979
-12,001
-0.8% -$41.4K ﹤0.01% 3484
2022
Q4 		$5.29M Buy
1,516,980
+73,020
+5% +$641K ﹤0.01% 3274
2022
Q3 		$53.5M Buy
1,443,960
+20,928
+1% +$580K ﹤0.01% 2149
2022
Q2 		$27M Buy
1,423,032
+99,018
+7% +$2.16M ﹤0.01% 2496
2022
Q1 		$35.7M Buy
1,324,014
+99,113
+8% +$2.05M ﹤0.01% 2471
2021
Q4 		$27.6M Buy
1,224,901
+310,178
+34% +$6.9M ﹤0.01% 2667
2021
Q3 		$24M Buy
914,723
+142,947
+19% +$3.83M ﹤0.01% 2756
2021
Q2 		$24.7M Buy
771,776
+78,469
+11% +$2.73M ﹤0.01% 2741
2021
Q1 		$24.4M Buy
693,307
+30,684
+5% +$1.07M ﹤0.01% 2678
2020
Q4 		$21.3M Sell
662,623
-10,158
-2% -$349K ﹤0.01% 2603
2020
Q3 		$25.3M Sell
672,781
-18,871
-3% -$729K ﹤0.01% 2335
2020
Q2 		$31M Buy
691,652
+111,794
+19% +$4.73M ﹤0.01% 2224
2020
Q1 		$19.8M Buy
579,858
+10,105
+2% +$407K ﹤0.01% 2289
2019
Q4 		$22.2M Buy
+569,753
New +$17.3M ﹤0.01% 2485

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group's RLMD Position: Q4 2025 in Review

Vanguard Group increased its Relmada Therapeutics (RLMD) stake by 187% in Q4 2025, buying an estimated $2.63M and bringing the position to 1,203,307 shares worth $5.81M. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

Vanguard Group first reported a position in RLMD in Q4 2019 and has held it in 25 quarters since. The position peaked at $53.5M in Q3 2022. 78 funds tracked by Wall St. Rank hold RLMD as of Q4 2025.

  • Vanguard Group held 1,203,307 shares of Relmada Therapeutics worth $5.81M as of Q4 2025.
  • Vanguard Group bought 784,727 Relmada Therapeutics shares in Q4 2025, an estimated $2.63M.
  • Relmada Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3194 holding.
  • Vanguard Group first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 25 quarters since.
  • Vanguard Group's Relmada Therapeutics position peaked at $53.5M in Q3 2022.
  • 78 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.